197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC)
| Autor: | Moore, K.N., Bouberhan, S., Hamilton, E., Liu, J., O'Cearbhaill, R.E., O'Malley, D., Papadimitriou, K., Schröder, D., Van Nieuwenhuysen, E., Yoo, S-Y., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Uldrick, T., Miller, E.A. |
|---|---|
| Zdroj: | In Immuno-Oncology and Technology December 2022 16 Supplement 1 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|